SciMed Biotech Podcast with Scott Thacher of Orphagen Pharmaceuticals

Scott Thacher, CEO of Orphagen Pharmaceuticals

Targeting Cancer’s “On Switch”:
A New Approach to Treating Rare Adrenal Tumors

In this episode of the SciMed Biotech Podcast, Adam Stasio sits down with Dr. Scott Thacher, founder and CEO of Orphagen Pharmaceuticals, to explore a novel approach to treating adrenocortical cancer—an aggressive and often untreatable rare disease. Scott shares how his team is targeting a key molecular “on switch” using small-molecule therapies designed to regulate gene expression at its source. From the science behind nuclear receptors like SF1 to the realities of funding, clinical trials, and bringing a first-in-class drug to market, this conversation offers a compelling look at how breakthrough therapies move from concept to clinic—and the impact they could have on patients with limited options.